Clinical Trial Results:
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients with Severe Eosinophilic Asthma
Summary
|
|
EudraCT number |
2017-000647-40 |
Trial protocol |
GB |
Global end of trial date |
30 Oct 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Apr 2021
|
First version publication date |
16 Apr 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
ANB020-004
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03469934 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
AnaptysBio, Inc
|
||
Sponsor organisation address |
10421 Pacific Center Court, Suite 200, San Diego, United States, CA 92121
|
||
Public contact |
AnaptysBio Clinical Trials Information, AnaptysBio, Inc, +1 8583626387, clinicaltrialinfo@anaptysbio.com
|
||
Scientific contact |
AnaptysBio Clinical Trials Information, AnaptysBio, Inc, +1 8583626387, clinicaltrialinfo@anaptysbio.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Oct 2018
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Oct 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objectives of the study were:
- To measure the reduction of eosinophils (blood eosinophil count) from Baseline (Day 1 pre-dose) to Day 22 in adult severe eosinophilic asthma patients administered with etokimab;
- To assess the safety and tolerability of a single, intravenous (IV) dose of etokimab compared to placebo in adult patients with severe eosinophilic asthma.
|
||
Protection of trial subjects |
This study was conducted in accordance with the protocol and with the following:
- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines;
- Applicable International Conference on Harmonisation Good Clinical Practice Guidelines;
- Applicable laws and regulations.
|
||
Background therapy |
Patients with eosinophilic asthma with exacerbations requiring rescue medication were expected to be on bronchodilators and were required to be on high-dose inhaled corticosteroids and long-acting beta-2 agonists. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
14 Nov 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 9
|
||
Country: Number of subjects enrolled |
United States: 16
|
||
Worldwide total number of subjects |
25
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
25
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
This study was conducted in adults with severe eosinophilic asthma. Patients were randomized on Day 1 to receive a single IV dose of either etokimab or placebo in a 1:1 ratio. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
This study consisted of a screening period (7 to 14 days), treatment period, and follow-up period (total of 127 days). The total duration of the study was approximately 141 days. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Etokimab | |||||||||||||||
Arm description |
Etokimab 300 milligrams (mg)/100 milliliters (mL) was administered by IV infusion once on Day 1. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Etokimab
|
|||||||||||||||
Investigational medicinal product code |
ANB020
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
A single dose of 300 mg etokimab was administered on Day 1 over 1 hour by IV infusion in polyvinyl chloride or polyolefin bags following dilution to a total volume of 100 mL with 0.9% sodium chloride (NaCl).
|
|||||||||||||||
Arm title
|
Placebo | |||||||||||||||
Arm description |
Placebo was administered by IV infusion once on Day 1. | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
A single dose of 100 mL of placebo (0.9% NaCl) was administered on Day 1 over 1 hour by IV infusion.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etokimab
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Etokimab 300 milligrams (mg)/100 milliliters (mL) was administered by IV infusion once on Day 1. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo was administered by IV infusion once on Day 1. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Etokimab
|
||
Reporting group description |
Etokimab 300 milligrams (mg)/100 milliliters (mL) was administered by IV infusion once on Day 1. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo was administered by IV infusion once on Day 1. |
|
|||||||||||||
End point title |
Change in Peripheral Eosinophil Count from Baseline to Day 22 | ||||||||||||
End point description |
Blood samples to determine the eosinophil count were obtained as part of the standard hematology safety laboratory panel. The Pharmacodynamic (PD) Analysis Set included all patients who received etokimab or placebo and provided at least 1 evaluable post-dose PD measurement without any events or protocol deviation deemed to affect PD assessment.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline (Day 1) and Day 22
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Etokimab versus (vs) Placebo | ||||||||||||
Statistical analysis description |
Results based on a linear mixed model with fixed effects for treatment, timepoint, treatment × timepoint, and baseline value and a repeated timepoint effect within a patient under an unstructured covariance matrix.
|
||||||||||||
Comparison groups |
Etokimab v Placebo
|
||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.5703 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Least-squares (LS) mean difference | ||||||||||||
Point estimate |
-0.058
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.265 | ||||||||||||
upper limit |
0.15 |
|
||||||||||||||||||||||
End point title |
Number of Patients who Experienced an Adverse Event (AE) [1] | |||||||||||||||||||||
End point description |
An AE is any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A treatment-emergent AE (TEAE) is an AE that started or worsened in severity on or after the date and time of the study drug infusion. A serious adverse event (SAE), experience or reaction, is any untoward medical occurrence (whether considered to be related to the study drug or not) that at any dose:
- Results in death;
- Is life-threatening;
- Requires inpatient hospitalization or prolongation of existing hospitalization;
- Results in persistent or significant disability/incapacity;
- Is a congenital anomaly/birth defect;
- Other medically important event.
The Safety Analysis Set included all patients who received etokimab or placebo.
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
Day 1 to Day 127
|
|||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analysis was pre-specified for this endpoint. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Patients with Clinically Meaningful Findings in Physical Examination Assessments [2] | |||||||||
End point description |
The physical examination included evaluation of general appearance, head, eyes, ears, nose, and throat, and the pulmonary, cardiovascular, gastrointestinal, renal/genitourological, endocrine (including thyroid), musculoskeletal/spinal, lymphatic, and dermatologic systems. The Safety Analysis Set included all patients who received etokimab or placebo.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Day 1 to Day 127
|
|||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analysis was pre-specified for this endpoint. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Patients with Clinically Meaningful Findings in Vital Signs Measurements [3] | |||||||||
End point description |
Vital signs included pulse rate, respiratory rate, body temperature, systolic blood pressure (BP), and diastolic BP. The Safety Analysis Set included all patients who received etokimab or placebo.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Day 1 to Day 127
|
|||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analysis was pre-specified for this endpoint. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Patients with Clinically Meaningful Findings in Clinical Safety Laboratory Evaluations [4] | |||||||||
End point description |
Hematology, clinical chemistry, virology, urinalysis, and drugs of abuse testing was performed. The clinical laboratory test results were reviewed for potential clinical significance, based on Investigator’s discretion throughout the study. The Investigator evaluated any change in laboratory values. If the Investigator determined a laboratory abnormality to be clinically significant, it was considered a laboratory AE; however, if the abnormal laboratory value was consistent with a current diagnosis, it was documented accordingly. The Safety Analysis Set included all patients who received etokimab or placebo.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Day 1 to Day 127
|
|||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analysis was pre-specified for this endpoint. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Patients with Clinically Meaningful Findings in Electrocardiogram (ECG) Assessments [5] | |||||||||
End point description |
A standard 12-lead ECG was performed by a qualified physician or nurse. The following parameters were documented: heart rate, PR interval, QRS interval, QT interval, and QTc interval. The Safety Analysis Set included all patients who received etokimab or placebo.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Day 1 to Day 127
|
|||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analysis was pre-specified for this endpoint. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Asthma Exacerbations [6] | |||||||||
End point description |
The definition of asthma exacerbation for this endpoint included:
- Use of systemic corticosteroids (or a temporary increase in a stable oral corticosteroid background dose) for at least 3 days; a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of systemic corticosteroids; or
- An emergency room/urgent care visit (defined as evaluation and treatment for <24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids (as per above); or
- An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥24 hours due to asthma).
The Full Analysis Set included all patients who received etokimab or placebo and had at least 1 post-baseline blood eosinophils count assessment (Day 2).
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
Day 1 to Day 127
|
|||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analysis was pre-specified for this endpoint. |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Number of Patients with Anti-drug Antibodies (ADA) [7] | |||||||||||||||||||||||||||
End point description |
Number of patients with positive ADA assay result is reported. The Safety Analysis Set included all patients who received etokimab or placebo.
|
|||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||
End point timeframe |
Day 1 pre-dose and Days 8, 36, 85, 106 and 127
|
|||||||||||||||||||||||||||
Notes [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No additional statistical analysis was pre-specified for this endpoint. |
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change in Peripheral Eosinophil Count from Baseline to Day 127 | ||||||||||||
End point description |
Blood samples to determine the eosinophil count were obtained as part of the standard hematology safety laboratory panel. The PD Analysis Set included all patients who received etokimab or placebo and provided at least 1 evaluable post-dose PD measurement without any events or protocol deviation deemed to affect PD assessment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1) and Day 127
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Etokimab vs Placebo | ||||||||||||
Statistical analysis description |
Results based on a linear mixed model with fixed effects for treatment, timepoint, treatment × timepoint, and baseline value and a repeated timepoint effect within a patient under an unstructured covariance matrix.
|
||||||||||||
Comparison groups |
Etokimab v Placebo
|
||||||||||||
Number of subjects included in analysis |
25
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.5901 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LS mean difference | ||||||||||||
Point estimate |
-0.05
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.239 | ||||||||||||
upper limit |
0.139 |
|
|||||||||||||
End point title |
Change in Forced Expiratory Volume in 1 Second from Baseline to Day 127 | ||||||||||||
End point description |
Spirometry was performed according to the American Thoracic Society/European Respiratory Society guidelines (ATS/ERS). Pre-bronchodilator spirometry was performed after appropriate bronchodilator withholding period in the morning. Forced expiratory maneuvers were performed with the patient seated in an upright position if possible. Three acceptable maneuvers were obtained for each test. The Full Analysis Set included all patients who received etokimab or placebo and had at least 1 post-baseline blood eosinophils count assessment (Day 2).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1) and Day 127
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Etokimab vs Placebo | ||||||||||||
Statistical analysis description |
P-value was obtained using analysis of covariance (ANCOVA) model with treatment as fixed effect and baseline result as covariate.
|
||||||||||||
Comparison groups |
Etokimab v Placebo
|
||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.596 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS mean difference | ||||||||||||
Point estimate |
0.09
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.25 | ||||||||||||
upper limit |
0.43 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.164
|
|
|||||||||||||
End point title |
Change in Fractional Exhaled Nitric Oxide (FeNO) from Baseline to Day 127 | ||||||||||||
End point description |
Measurement of FeNO was performed in accordance with the guidelines published by ATS/ERS. The FeNO test was performed before the spirometry testing. The Full Analysis Set included all patients who received etokimab or placebo and had at least 1 post-baseline blood eosinophils count assessment (Day 2).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1) and Day 127
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Etokimab vs Placebo | ||||||||||||
Statistical analysis description |
P-value is obtained using ANCOVA model with treatment as fixed effect and baseline result as covariate.
|
||||||||||||
Comparison groups |
Etokimab v Placebo
|
||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.7993 | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
LS mean difference | ||||||||||||
Point estimate |
2.53
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-17.9 | ||||||||||||
upper limit |
22.96 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
9.823
|
|
|||||||||||||||||||||||||||||||
End point title |
Whole Blood Ex-vivo Induced Interferon-Gamma (IFN-γ) Levels (United Kingdom [UK] Sites Only) | ||||||||||||||||||||||||||||||
End point description |
Blood samples for ex-vivo induced IFN-γ assessment were collected in a sodium heparin tube and the measurement of ex-vivo induced IFN-γ was performed using validated assay methods. The PD Analysis Set included all patients who received etokimab or placebo and provided at least 1 evaluable post-dose PD measurement without any events or protocol deviation deemed to affect PD assessment. Only patients randomized within the UK were included. 9999 = below the lower limit of quantification; 99999 = not determined; 999999 = no patients were analyzed at that specific timepoint.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
Baseline (Day 1) and Days 8, 36, 85, 106 and 127
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Maximum Observed Concentration (Cmax) of Etokimab [8] | ||||||||
End point description |
Cmax was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, end of infusion (EOI), EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Time to Maximum Observed Concentration (Tmax) of Etokimab [9] | ||||||||
End point description |
Tmax was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Area Under the Concentration-time Curve in Serum from Time Zero (pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of Etokimab [10] | ||||||||
End point description |
AUC(0-inf) was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Area Under the Serum Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-last]) of Etokimab [11] | ||||||||
End point description |
AUC0-last was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Apparent Total Body Clearance (CL) of Etokimab [12] | ||||||||
End point description |
CL was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Apparent Terminal Rate Constant (λz) of Etokimab [13] | ||||||||
End point description |
λz was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Apparent Terminal Half-life (t1/2) of Etokimab [14] | ||||||||
End point description |
t1/2 was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Volume of Distribution During Terminal Phase (Vz) of Etokimab [15] | ||||||||
End point description |
Vz was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Volume of Distribution at Steady State Following IV Dosing (Vss) of Etokimab [16] | ||||||||
End point description |
Vss was derived using non-compartmental methods. The PK Analysis Set included all patients who received etokimab and had at least 1 post-dose serum concentration data available for etokimab without any events or protocol deviation deemed to affect PK assessments.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1 pre-dose, 0.5 hours post-start of infusion, EOI, EOI + 3 hours, EOI + 6 hours, and Days 2, 8, 22, 36 and 64
|
||||||||
Notes [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK assessment was pre-specified for the etokimab arm only. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Day 1 to Day 127
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
20
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etokimab
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Etokimab 300 mg/100 mL was administered by IV infusion once on Day 1. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo was administered by IV infusion once on Day 1. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
08 May 2017 |
Changes encompassed by this amendment included administrative changes and updates to the inclusion criteria, patient restrictions, and blinding. |
||
04 Jan 2018 |
Changes encompassed by this amendment included administrative changes, and updates to the synopsis, background information, discussion of study design, summary of study design, inclusion criteria, exclusion criteria, patient restrictions, patient withdrawal, excluded medications, spirometry, timing of procedures, appendix VI - IFN-y collection timepoints, and schedule of events. |
||
16 Feb 2018 |
Changes encompassed by this amendment included updates to the inclusion criteria, method of assigning patients to treatment group, and unblinding. |
||
30 Oct 2018 |
Amendment dated 31-Oct-2018.
This amendment combined the United States and UK ANB020-004 protocols and updated the clinical study background to incorporate the most recent updates to the Investigator Brochure. No changes were made to study procedures in this amendment. Changes encompassed by this amendment included administrative changes, clinical updates, and country specific assessments combined into 1 global protocol. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |